EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieMultizentrische StudieRandomisierte kontrollierte Studie

Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole

Judith-Anne W Chapman, Jane Bayani iD, Sandip SenGupta, John M S Bartlett, Tammy Piper, Mary Anne Quintayo, Shakeel Virk iD, Paul E Goss, James N Ingle iD, Matthew J Ellis iD, George W Sledge iD, G Thomas Budd iD und 14 weitere

Journal of Clinical Oncology · 2024

DOI: 10.1200/jco.24.00835 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Judith-Anne W Chapman und 25 weiteren Autor:innen. Beteiligte Einrichtung: Canadian Cancer Trials Group Queen's University, Kitchener, Canada. Hauptthemen laut MEDLINE: Anastrozole, Androstadienes, Breast Neoplasms, Postmenopause. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE ASCO/College of American Pathologists guidelines recommend reporting estrogen receptor (ER) and progesterone receptor (PgR) as positive with (1%-100%) staining. Statistically standardized quantitated positivity could indicate differential associations of positivity with breast cancer outcomes. METHODS MA.27 (ClinicalTrials.gov identifier: NCT00066573 ) was a phase III adjuvant trial of exemestane versus anastrozole in postmenopausal women with early-stage breast cancer. Immunochemistry ER and PgR HSCORE and % positivity (%+) were centrally assessed by machine image quantitation and statistically standardized to mean 0 and standard deviation (SD) 1 after Box-Cox variance stabilization transformations of square for ER; for PgR, (1) natural logarithm (0.1 added to 0 HSCOREs and 0%+) and (2) square root. Our primary end point was MA.27 distant disease-free survival (DDFS) at a median 4.1-year follow-up, and secondary end point was event-free survival (EFS). Univariate survival with cut points at SDs about a mean of 0 (≤–1; (–1, 0]; (0, 1]; >1) was described with Kaplan-Meier plots and examined with Wilcoxon (Peto-Prentice) test statistic. Adjusted Cox multivariable regressions had two-sided Wald tests and nominal significance P < .05. RESULTS Of 7,576 women accrued, 3,048 women's tumors had machine-quantitated image analysis results: 2,900 (95%) for ER, 2,726 (89%) for PgR, and 2,582 (85% of 3,048) with both ER and PgR. Higher statistically standardized ER and PgR HSCORE and %+ were associated with better univariate DDFS and EFS ( P < .001). In multivariable assessments, ER HSCORE and %+ were not significantly associated ( P = .52-.88) with DDFS in models with PgR, whereas higher PgR HSCORE and %+ were significantly associated with better DDFS ( P = .001) in models with ER. CONCLUSION Adjunctive statistical standardization differentiated quantitated levels of ER and PgR. Patients with higher ER- and PgR-standardized units had superior DDFS compared with those with HSCOREs and %+ ≤–1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnastrozoleAndrostadienesBreast NeoplasmsPostmenopauseReceptors, EstrogenReceptors, ProgesteroneAgedFemaleHumansMiddle AgedCanadaChemotherapy, AdjuvantDisease-Free Survival

Substanzen

AnastrozoleAndrostadienesexemestaneReceptors, EstrogenReceptors, Progesterone

Autor:innen und Institutionen

  • Canadian Cancer Trials Group Queen's University, Kitchener, Canada.
  • Ontario Institute for Cancer Research, Toronto, Canada.
  • University of Toronto, Toronto, Canada.
  • Queen's University, Kingston, Canada.
  • University of Edinburgh, Edinburgh, United Kingdom.
  • Canadian Cancer Trials Group Queen's University, Kingston, Canada.

ORCID-Profile: Jane Bayani, Shakeel Virk, James N Ingle, Matthew J Ellis, George W Sledge, G Thomas Budd, Manuela Rabaglio, Vered Stearns, Edith A Perez, Karen A Gelmon, Timothy J Whelan, Lois E Shepherd, Bingshu E Chen, Karen J Taylor

Zitieren

APA

Chapman, J. W., Bayani, J., SenGupta, S., Bartlett, J. M. S., Piper, T., Quintayo, M. A., Virk, S., Goss, P. E., Ingle, J. N., Ellis, M. J., Sledge, G. W., Budd, G. T., Rabaglio, M., Ansari, R. H., Tozer, R., D'Souza, D. P., Chalchal, H., Spadafora, S., Stearns, V., …, & Taylor, K. J. (2024). Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole. Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.00835

Vancouver

Chapman JW, Bayani J, SenGupta S, Bartlett JMS, Piper T, Quintayo MA, et al. Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole. Journal of Clinical Oncology. 2024. doi:10.1200/jco.24.00835

BibTeX
@article{Chapman2024,
  author = {Chapman, Judith-Anne W and Bayani, Jane and SenGupta, Sandip and Bartlett, John M S and Piper, Tammy and Quintayo, Mary Anne and Virk, Shakeel and Goss, Paul E and Ingle, James N and Ellis, Matthew J and Sledge, George W and Budd, G Thomas and Rabaglio, Manuela and Ansari, Rafat H and Tozer, Richard and D'Souza, David P and Chalchal, Haji and Spadafora, Silvana and Stearns, Vered and Perez, Edith A and Gelmon, Karen A and Whelan, Timothy J and Elliott, Catherine and Shepherd, Lois E and Chen, Bingshu E and Taylor, Karen J},
  title = {Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1200/jco.24.00835}
}
Kostenlos starten →